Proton beam therapy shows promise in tumor control trial
NCT ID NCT06340815
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the Varian ProBeam proton therapy system in 47 people with solid tumors. The goal was to see if the device safely controls tumors and meets performance standards. Patients received proton radiation and were followed for up to 5 years after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Proton therapy (ProBeam system)
- What this could lead to
- If successful, this could support approval of a precise proton therapy system that targets tumors while sparing healthy tissue.
- What could go wrong
- This is a small, single-center study with no comparison group. Results may not apply to all tumor types or patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BENIGN INTRACRANIAL TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Shandong Cancer Hospital
Jinan, Shandong, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New radiation approach aims to spare healthy tissue in sinus cancer treatment
- New nutrition strategy aims to protect kids with cancer from malnutrition
- New drug combo takes aim at Hard-to-Treat cancers
- New proton beam machine aims to improve cancer care
- New iron injection shows promise in shrinking tumors
- New shorter radiation therapy could tame brain tumors